Abstract
The promise of β-cell replacement has become more tangible as several changes to human allograft islet transplantation have brought a new effectiveness as reported by the Edmonton group. However, two major obstacles must be overcome for this procedure to benefit the greatest number of patients. Better ways to protect the transplanted islets from allograft rejection and recurrent autoimmunity must be developed, and new sources of insulin-producing tissue must be found. Research has led to exciting new advances in both of these areas.

This publication has 64 references indexed in Scilit: